Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force
Abstract
An international task force of investigators from academia, industry, nonprofit foundations, and regulatory agencies met in Monte Carlo, Monaco, on October 31, 2012, to review lessons learned from the recent bapineuzumab and solanezumab trials, and to incorporate insights gained from these trials into future clinical studies. Although there is broad consensus that Alzheimer's disease (AD) should be treated during its earliest stages, the concept of secondary prevention has evolved to be described more accurately as treatment of preclinical, presymptomatic, or early AD. There continues to be a strong emphasis on biomarkers and a need for new biomarkers; however, there has also been a realization, based on completed trials, that the most reliable indicator of clinical efficacy across the entire spectrum of disease from asymptomatic to AD dementia is likely a measure of cognition. The task force made many recommendations that should improve the likelihood of success in future trials, including larger phase 2 or combined phase 2/phase 3 studies, clear evidence of target engagement in the central nervous system, evidence of downstream effects on biomarkers before initiating phase 3 studies, consideration of adaptive and targeted trial designs, and use of sensitive measures of cognition as the most robust indicator of treatment benefit.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Trials featuring intravenous infusions of antibodies to Aβ failed to meet their primary endpoints.
“Trials featuring intravenous infusions of antibodies to Aβ failed to meet their primary endpoints [252].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [252]
Aβ-based approaches appear to accelerate, not impact, or at best very minimally slow symptomatic subject progression.
“despite the fact these approaches appear to accelerate, not impact, or at best very minimally slow symptomatic subject progression.”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [252]
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · see citing works
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · see citing works
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · see citing works
Self-citationResearch criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411 · see citing works
Self-citationClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · see citing works
Self-citationAmyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986 · see citing works
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753 · see citing works
Self-citationRinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701 · see citing works
Self-citationBiomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
Hampel, H. J., Frank, R., Broich, K., Teipel, S. J., Katz, R. G., Hardy, J., Herholz, K., Bokde, A. L. W., Jessen, F., Hoessler, Y. C., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3115 · Cited by 630 · see citing works
Self-citationSperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70015-7 · Cited by 512 · see citing works
Self-citationVellas, B. J., Coley, N., Ousset, P., Berrut, G., Dartigues, J., Dubois, B., Grandjean, H., Pasquier, F., Piette, F., Robert, P. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70206-5 · Cited by 401 · see citing works
Self-citationFreidlin, B., & Simon, R. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0605 · Cited by 351 · see citing works
Jiang, W., Freidlin, B., & Simon, R. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm022 · Cited by 253 · see citing works
On the efficiency of targeted clinical trials
Maitournam, A., & Simon, R. (2005) · Statistics in Medicine · doi:10.1002/sim.1975 · Cited by 200 · see citing works
Sperling, R. A., Aisen, P. S. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J. A., Montine, T. J., et al. (2011) · Cited by 197 · see citing works
Self-citationBiomarkers in Alzheimer's disease drug development
Blennow, K. (2010) · Nature Medicine · doi:10.1038/nm.2221 · Cited by 145 · see citing works
Frisoni, G. B., & Jack, C. R. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.06.007 · Cited by 98 · see citing works
Mattsson, N., Zegers, I., Andréasson, U., Bjerke, M., Blankenstein, M. A., Bowser, R. P., Carrillo, M. C., Gobom, J., Heath, T., Jenkins, R. G., et al. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.39 · Cited by 77 · see citing works
Self-citationNeuroimaging predictors of brain amyloidosis in mild cognitive impairment
Tosun, D., Joshi, S. C., & Weiner, M. W. (2013) · Annals of Neurology · doi:10.1002/ana.23921 · Cited by 42 · see citing works
Self-citationProficiency Testing Programs for Alzheimer’s Disease Cerebrospinal Fluid Biomarkers
Mattsson, N., Andréasson, U., Carrillo, M. C., Persson, S., Shaw, L. M. J., Zegers, I., Zetterberg, H., & Blennow, K. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.41 · Cited by 24 · see citing works
Self-citation
Flagged first, then by citations
1 of the 21 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925 · see citing works
Self-citationThe Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786 · see citing works
The case for rejecting the amyloid cascade hypothesis
Herrup, K. (2015) · Nature Neuroscience · doi:10.1038/nn.4017 · Cited by 768 · see citing works
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., Kiddle, S. J., Batrla, R., & Blennow, K. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0079-7 · Cited by 716 · see citing works
Self-citationWeiner, M. W., Veitch, D. P., Aisen, P. S. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Morris, J. C., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.10.006 · Cited by 499 · see citing works
Self-citationAlzheimer’s Disease Genetics: From the Bench to the Clinic
Karch, C. M., Cruchaga, C., & Goate, A. M. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.041 · Cited by 473 · see citing works
Cognitive frailty, a novel target for the prevention of elderly dependency
Ruan, Q., Yu, Z., Ma, C., Bao, Z., Li, J., & He, W. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.12.004 · Cited by 381 · see citing works
Gribkoff, V. K., & Kaczmarek, L. K. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.021 · Cited by 379 · see citing works
Hampel, H. J., Mesulam, M. M., Cuello, A. C., Khachaturian, A. S., Vergallo, A., Farlow, M. R., Snyder, P. J., Giacobini, E., & Khachaturian, Z. S. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.43 · Cited by 369 · see citing works
Self-citationTau-aggregation inhibitor therapy for Alzheimer's disease
Wischik, C. M., Harrington, C. R., & Storey, J. M. D. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.008 · Cited by 263 · see citing works
Therapeutic approaches to target alpha-synuclein pathology
Brundin, P., Dave, K. D., & Kordower, J. H. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.003 · Cited by 242 · see citing works
The “rights” of precision drug development for Alzheimer’s disease
Cummings, J. L., Feldman, H., & Scheltens, P. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0529-5 · Cited by 240 · see citing works
Self-citationJessen, F., Spottke, A. E., Boecker, H., Brosseron, F., Büerger, K., Catak, C., Fließbach, K., Franke, C., Fuentes, M., Heneka, M. T., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0314-2 · Cited by 233 · see citing works
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219 · see citing works
Improving and Accelerating Drug Development for Nervous System Disorders
Pankevich, D. E., Altevogt, B. M., Dunlop, J., Gage, F. H., & Hyman, S. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.007 · Cited by 205 · see citing works
Barnett, J. H., Blackwell, A. D., Sahakian, B. J., & Robbins, T. W. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_5001 · Cited by 182 · see citing works
Molinuevo, J. L., Gramunt, N., Gispert, J. D., Fauria, K., Esteller, M., Minguillón, C., Sánchez‐Benavides, G., Huesa, G., Morán, S., Dal‐Ré, R., et al. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.02.003 · Cited by 177 · see citing works
Does mild cognitive impairment always lead to dementia? A review
Pandya, S. Y., Clem, M. A., Silva, L. M., & Woon, F. L. M. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.07.055 · Cited by 150 · see citing works
Therapy and clinical trials in frontotemporal dementia: past, present, and future
Tsai, R. M., & Boxer, A. L. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13640 · Cited by 145 · see citing works
Hampel, H. J., Lista, S., Teipel, S. J., Garaci, F., Nisticò, R., Blennow, K., Zetterberg, H., Bertram, L., Duyckaerts, C. J., Bakardjian, H., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.009 · Cited by 141 · see citing works
Self-citationContemplating Alzheimer’s Disease and the Contribution of White Matter Hyperintensities
Brickman, A. M. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0415-7 · Cited by 136 · see citing works
Dementia risk and prevention by targeting modifiable vascular risk factors
Tariq, S., & Barber, P. A. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14132 · Cited by 135 · see citing works
Targeted delivery of protein and gene medicines through the blood–brain barrier
Pardridge, W. M. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.18 · Cited by 131 · see citing works
Prediction of Conversion to Alzheimer’s Disease with Longitudinal Measures and Time-To-Event Data
Li, K., Chan, W., Doody, R. S., Quinn, J., Luo, S., & Initiative, T. A. D. N. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161201 · Cited by 126 · see citing works
Self-citationFargo, K. N., Carrillo, M. C., Weiner, M. W., Potter, W. Z., & Khachaturian, Z. S. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.10.001 · Cited by 123 · see citing works
Self-citationMild to moderate Alzheimer dementia with insufficient neuropathological changes
Serrano‐Pozo, A., Qian, J., Monsell, S. E., Blacker, D., Gómez‐Isla, T., Betensky, R. A., Growdon, J. H., Johnson, K. A., Frosch, M. P., Sperling, R. A., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24125 · Cited by 120 · see citing works
Self-citationGenetic diagnosis and prognosis of Alzheimer’s disease: challenges and opportunities
Reitz, C. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1002469 · Cited by 120 · see citing works
More, S. S., & Vince, R. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500242z · Cited by 119 · see citing works
Azhari, H. N., Strauss, M., Hook, S. M., Boyd, B. J., & Rizwan, S. B. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.05.001 · Cited by 118 · see citing works
Advances in the prevention of Alzheimer's Disease
Sindi, S., Mangialasche, F., & Kivipelto, M. (2015) · F1000Prime Reports · doi:10.12703/p7-50 · Cited by 111 · see citing works
Neuroinflammation in Alzheimer’s Disease: from Pathogenesis to a Therapeutic Target
Pimplikar, S. W. (2014) · Journal of Clinical Immunology · doi:10.1007/s10875-014-0032-5 · Cited by 103 · see citing works
Banik, A., Brown, R. E., Bamburg, J., Lahiri, D. K., Khurana, D., Friedland, R. P., Chen, W., Ding, Y., Mudher, A., Padjen, A. L., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150136 · Cited by 102 · see citing works
Alosco, M. L., Tripodis, Y., Jarnagin, J., Baugh, C. M., Martin, B. M., Chaisson, C. E., Estochen, N., Song, L., Cantu, R. C., Jeromin, A., et al. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.11.003 · Cited by 100 · see citing works
Podhorná, J., Krahnke, T., Shear, M. A., Harrison, J., & Initiative, A. D. N. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0170-5 · Cited by 96 · see citing works
Alzheimer's disease: The amyloid hypothesis on trial
Harrison, J. R., & Owen, M. J. (2016) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.115.167569 · Cited by 96 · see citing works
Galeano, P., Adami, P. V. M., Carmo, S. D., Blanco, E., Rotondaro, C., Capani, F., Castaño, E. M., Cuello, A. C., & Morelli, L. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00321 · Cited by 88 · see citing works
Monsell, S. E., Kukull, W. A., Roher, A. E., Maarouf, C. L., Serrano, G., Beach, T. G., Caselli, R. J., Montine, T. J., & Reiman, E. M. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1721 · Cited by 82 · see citing works
Haston, K. M., & Finkbeiner, S. M. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103548 · Cited by 81 · see citing works
Wattmo, C., Minthon, L., & Wallin, Å. K. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0174-1 · Cited by 81 · see citing works
Derivation of cutoffs for the Elecsys® amyloid β (1–42) assay in Alzheimer's disease
Shaw, L. M. J., Waligórska, T., Fields, L., Korecka, M., Figurski, M., Trojanowski, J. Q., Eichenlaub, U., Wahl, S., Quan, M., Pontecorvo, M. J., et al. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.07.002 · Cited by 81 · see citing works
Self-citationHampel, H. J., Schneider, L. S., Giacobini, E., Kivipelto, M., Sindi, S., Dubois, B., Broich, K., Nisticò, R., Aisen, P. S. S., & Lista, S. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.995637 · Cited by 77 · see citing works
Self-citationDukart, J., Sambataro, F., Bertolino, A., & Initiative, A. D. N. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150570 · Cited by 68 · see citing works
Gupta, V., Gupta, V. B., Chitranshi, N., Gangoda, S. V. S., Wall, R. V., Abbasi, M., Golzan, M., Dheer, Y., Shah, T. M., Avolio, A. P., et al. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2295-x · Cited by 69 · see citing works
Molinuevo, J. L., Camı́, J., Carné, X., Carrillo, M. C., Georges, J., Isaac, M., Khachaturian, Z. S., Kim, S. Y. H., Morris, J. C., Pasquier, F., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.01.009 · Cited by 60 · see citing works
Self-citationLista, S., Dubois, B., & Hampel, H. J. (2014) · The journal of nutrition health & aging · doi:10.1007/s12603-014-0515-3 · Cited by 60 · see citing works
Self-citationWhat does complement do in Alzheimer’s disease? Old molecules with new insights
Shen, Y., Yang, L., & Li, R. (2013) · Translational Neurodegeneration · doi:10.1186/2047-9158-2-21 · Cited by 59 · see citing works
Wang, G., Berry, S. M., Xiong, C., Hassenstab, J. J., Quintana, M., McDade, E., Delmar, P., Vestrucci, M., Sethuraman, G., Bateman, R. J., et al. (2018) · Statistics in Medicine · doi:10.1002/sim.7811 · Cited by 57 · see citing works
RE-ENGINEERING ALZHEIMER CLINICAL TRIALS: GLOBAL ALZHEIMER’S PLATFORM NETWORK
Cummings, J. L., Aisen, P. S. S., Barton, R. D., Bork, J., Doody, R. S., Dwyer, J. R., Egan, J. C., Feldman, H., Lappin, D. R., Truyen, L., et al. (2016) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2016.93 · Cited by 55 · see citing works
Self-citationInsights into the use of biomarkers in clinical trials in Alzheimer's disease
Pascoal, T. A., Aguzzoli, C. S., Lussier, F. Z., Crivelli, L., Suemoto, C. K., Fortea, J., Rosa‐Neto, P., Zimmer, E. R., Ferreira, P. C. L., & Bellaver, B. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105322 · Cited by 56 · see citing works
A new roadmap for drug development for Alzheimer's disease
Becker, R. E., Greig, N. H., Giacobini, E., Schneider, L. S. S., & Ferrucci, L. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3842-c2 · Cited by 53 · see citing works
Self-citationBuechler, J., & Salinas, P. C. (2018) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2018.00038 · Cited by 52 · see citing works
Rethinking on the concept of biomarkers in preclinical Alzheimer’s disease
Berti, V., Polito, C., Lombardi, G., Ferrari, C., Sorbi, S., & Pupi, A. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2477-1 · Cited by 51 · see citing works
Sacuiu, S. F. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802973-2.00008-2 · Cited by 51 · see citing works
What lessons can be learned from failed Alzheimer’s disease trials?
Toyn, J. H. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1034690 · Cited by 47 · see citing works
Profile of gantenerumab and its potential in the treatment of Alzheimer's disease
Nisticò, R., Novakovic, D., Feligioni, M., Scaccianoce, S., Piccinin, S., Mercuri, N. B., Nicoletti, F., Caruso, A., Schepisi, C., & Errico, F. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s53401 · Cited by 45 · see citing works
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS)
The Huntington Study Group PHAROS Investigators, Biglan, K., Shoulson, I., Kieburtz, K. D., Oakes, D., Kayson, E., Shinaman, M. A., Zhao, H., Romer, M., Young, A. B., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.2736 · Cited by 45 · see citing works
Self-citationEnrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration
Wolz, R., Schwarz, A. J., Gray, K. R., Yu, P., Hill, D., & Initiative, A. D. N. (2016) · Neurology · doi:10.1212/wnl.0000000000003126 · Cited by 45 · see citing works
Evaluation of Cholinergic Deficiency in Preclinical Alzheimer’s Disease Using Pupillometry
Frost, S. M., Robinson, L., Rowe, C. C., Ames, D. J., Masters, C. L., Taddei, K., Rainey‐Smith, S. R., Martins, R. N., & Kanagasingam, Y. (2017) · Journal of Ophthalmology · doi:10.1155/2017/7935406 · Cited by 44 · see citing works
Multidomain intervention and/or omega‐3 in nondemented elderly subjects according to amyloid status
Delrieu, J., Payoux, P., Carrié, I., Cantet, C., Weiner, M. W., Vellas, B. J., & Andrieu, S. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.07.008 · Cited by 45 · see citing works
Self-citationChallenges, solutions, and recommendations for Alzheimer's disease combination therapy
Hendrix, J. A., Bateman, R. J., Brashear, H. R., Duggan, C. D., Carrillo, M. C., Bain, L. J., Demattos, R. B., Katz, R. G., Ostrowitzki, S., Siemers, E., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.02.007 · Cited by 44 · see citing works
Self-citationSmith, E. S., Porterfield, J. E., & Kannan, R. M. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.02.009 · Cited by 44 · see citing works
Tarnanas, I., Tsolaki, A., Wiederhold, M. D., Wiederhold, B. K., & Tsolaki, M. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.10.005 · Cited by 43 · see citing works
Qi, X.-M., Wang, C., Chu, X., Li, G., & Ma, J. (2018) · BMC Neuroscience · doi:10.1186/s12868-018-0402-7 · Cited by 43 · see citing works
Knecht, L. H., Folke, J., Dodel, R. C., Ross, J. A., & Albus, A. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01288-7 · Cited by 44 · see citing works
The TOMMORROW study: Design of an Alzheimer's disease delay‐of‐onset clinical trial
Burns, D. K., Chiang, C., Welsh-Bohmer, K. A., Brannan, S. K., Culp, M., O’Neil, J., Runyan, G., Harrigan, P., Plassman, B. L., Lutz, M. W., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.09.010 · Cited by 42 · see citing works
Kennedy, R., Cutter, G., Wang, G., & Schneider, L. S. S. (2015) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.03.001 · Cited by 41 · see citing works
Self-citationPharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease
Prvulovic, D., & Schneider, B. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.915028 · Cited by 41 · see citing works
Fleisher, A., Joshi, A. D., Sundell, K. L., Chen, Y., Kollack‐Walker, S., Lu, M., Chen, S., Devous, M. D., Seibyl, J. P., MAREK, K. L., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.02.009 · Cited by 39 · see citing works
Self-citationWattmo, C., Wallin, Å. K., & Minthon, L. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt210 · Cited by 37 · see citing works
Current and Emerging Therapies for Alzheimer’s Disease
Nygaard, H. B. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.09.009 · Cited by 32 · see citing works
Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics
Ritter, A. R., & Cummings, J. L. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00186 · Cited by 29 · see citing works
Rockwood, K. J., Howlett, S. E., Hoffman, D., Schindler, R. J., & Mitnitski, A. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.02.005 · Cited by 29 · see citing works
Challenges for Optimizing Real-World Evidence in Alzheimer’s Disease: The ROADMAP Project
Gallacher, J., de Vulpillieres, F. D. R., Amzal, B., Angehrn, Z., Bexelius, C., Bintener, C., Bouvy, J. C., Campo, L., Díaz, C., Georges, J., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180370 · Cited by 28 · see citing works
A short perspective on the long road to effective treatments for Alzheimer's disease
Reynolds, D. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14581 · Cited by 26 · see citing works
Smedinga, M., Darweesh, S. K. L., Bloem, B. R., Post, B., & Richard, E. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10162-5 · Cited by 27 · see citing works
A guide to using functional magnetic resonance imaging to study Alzheimer's disease in animal models
Asaad, M., & Lee, J. H. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.031724 · Cited by 26 · see citing works
Therapeutic and diagnostic challenges for frontotemporal dementia
Dâ€TMAlton, S., & Lewis, J. M. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00204 · Cited by 25 · see citing works
(APMI), F. T. A. P. M. I., Baldacci, F., Lista, S., O’Bryant, S. E., Ceravolo, R., Toschi, N., & Hampel, H. J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7704-8_9 · Cited by 23 · see citing works
Self-citationSaar, G., Cheng, N., Belluscio, L., & Koretsky, A. P. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.05.045 · Cited by 25 · see citing works
Boada, M., Santos‐Santos, M., Rodríguez‐Gómez, O., Alegret, M., Cañabate, P., Lafuente, A., Ruiz, C. A., Buendía, M., de Dios, M. J., Morera, A., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170866 · Cited by 24 · see citing works
Gramunt, N., Herman Buschke, L., Sánchez‐Benavides, G., Lipton, R. B., Peña‐Casanova, J., Diéguez-Vide, F., Masramon, X., Gispert, J. D., Fauria, K., Camı́, J., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150237 · Cited by 24 · see citing works
Wang, G., Kennedy, R., Goldberg, T. E., Fowler, M. E., Cutter, G., & Schneider, L. S. S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228064 · Cited by 24 · see citing works
Self-citationPrevention Trials in Alzheimer’s Disease: Current Status and Future Perspectives
Wang, J., Tan, L., & Yu, J. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150826 · Cited by 23 · see citing works
Hampel, H. J., Mesulam, M. M., Cuello, A. C., Khachaturian, A. S., Farlow, M. R., Snyder, P. J., Giacobini, E., & Khachaturian, Z. S. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.08.016 · Cited by 24 · see citing works
Self-citationRetractedFuture Directions in Imaging Neurodegeneration
Masdeu, J. C. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0718-1 · Cited by 22 · see citing works
Marizzoni, M., Ferrari, C., Jovicich, J., Albani, D., Babiloni, C., Cavaliere, L., Didic, M., Forloni, G., Galluzzi, S., Hoffmann, K., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180152 · Cited by 20 · see citing works
Cummings, J. L. (2020) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.20060152 · Cited by 21 · see citing works
Li, Y., Liu, Y., Wang, Z., & Jiang, Y. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.838555 · Cited by 21 · see citing works
Kahle‐Wrobleski, K., Andrews, J. S., Belger, M. A., Ye, W., Gauthier, S. G., Rentz, D. M., & Galasko, D. (2017) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2017.2 · Cited by 21 · see citing works
Harnessing the Immune System for Treatment and Detection of Tau Pathology
Congdon, E. E., Krishnaswamy, S., & Sigurdsson, E. M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132435 · Cited by 20 · see citing works
Mild cognitive impairment—not always what it seems
Richard, E., & Brayne, C. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.23 · Cited by 20 · see citing works
Innovative approaches in CNS drug discovery
Charvériat, M., Lafon, V., Mouthon, F., & Zimmer, L. (2020) · Therapies · doi:10.1016/j.therap.2020.12.006 · Cited by 20 · see citing works
Kim, D., Kim, Y. S., Shin, D. W., Park, C., & Kang, J.-H. (2016) · Journal of Clinical Neurology · doi:10.3988/jcn.2016.12.4.381 · Cited by 20 · see citing works
Becker, R. E., Greig, N. H., Lahiri, D. K., Bledsoe, J. R., Majercik, S. D., Ballard, C. G., Aarsland, D., Schneider, L. S. S., Flanagan, D. R., Govindarajan, R., et al. (2018) · Current Alzheimer Research · doi:10.2174/1567205015666180110120026 · Cited by 19 · see citing works
Self-citationCummings, J. L., Fox, N. C., Vellas, B. J., Aisen, P. S. S., & Shan, G. (2018) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.13 · Cited by 17 · see citing works
Self-citationPascoal, T. A., Therriault, J., Mathotaarachchi, S. S., Kang, M. S., Shin, M., Benedet, A. L., Chamoun, M., Tissot, C., Lussier, F. Z., Mohaddes, S., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12037 · Cited by 16 · see citing works
Neuroimaging of Diseases Causing Dementia
Masdeu, J. C. (2019) · Neurologic Clinics · doi:10.1016/j.ncl.2019.08.003 · Cited by 15 · see citing works
Wesnes, K. A. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0058-1 · Cited by 15 · see citing works
Kukharsky, M. S., Овчинников, Р. К., & Бачурин, С. О. (2015) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20151156103-114 · Cited by 14 · see citing works
Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?
Kayed, R., Castillo‐Carranza, D. L., & Guerrero‐Munoz, M. J. (2013) · ImmunoTargets and Therapy · doi:10.2147/itt.s40131 · Cited by 15 · see citing works
- Authors
- Vellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., Schneider, L. S., Weiner, M., Doody, R., Khachaturian, Z., Cedarbaum, J., Grundman, M., Broich, K., Giacobini, E., Dubois, B., Sperling, R., Wilcock, G. K., Fox, N., Scheltens, P., Touchon, J., Hendrix, S., Andrieu, S., Aisen, P., & EU/US/CTAD Task Force Members
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- Alzheimer's Association Chicago IL USA
- CHDI Foundation (US)
- Janssen (United States) (US)
- Eli Lilly (United States) (US)
- Goethe University Frankfurt (DE)
- University of Southern California (US)
- San Francisco VA Medical Center (US)
- Baylor College of Medicine (US)
- The Campaign to Prevent Alzheimer's Disease by 2020 Potomac MD USA
- Bristol-Myers Squibb (United States) (US)
- Global R&D Partners, LLC San Diego CA USA
- Federal Institute for Drugs and Medical Devices (DE)
- University of Geneva (CH)
- Pitié-Salpêtrière Hospital (FR)
- Brigham and Women's Hospital (US)
- University of Oxford (GB)
- UCL Queen Square Institute of Neurology (GB)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Pentara Corporation Salt Lake City UT USA
- University of California San Diego (US)
- Corresponding author
- Vellas, Bruno
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2013-07
- Volume
- 9
- Issue
- 4
- Pages
- 438-444
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2061602279
- Cited by
- 147
- References
- 21
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 3 · 2020: 6 · 2019: 8 · 2018: 15 · 2017: 10 · 2016: 30 · 2015: 25 · 2014: 20 · 2013: 15
- FWCI
- 20.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Katharina-Hardt-Foundation, Bad Homburg, Germany
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- Alzheimer's disease
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Atrophy, Brain, Brain Chemistry, Brain Edema, Humans, Multicenter Studies as Topic, Biomarkers, Randomized Controlled Trials as Topic, Amyloid beta-Peptides, Treatment Failure, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Disease Progression, Patient Selection, Nootropic Agents, Endpoint Determination, Neuroimaging, Cognitive Dysfunction, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
